The Goldman Sachs Group Boosts Thermo Fisher Scientific (NYSE:TMO) Price Target to $640.00

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) had its price target increased by stock analysts at The Goldman Sachs Group from $550.00 to $640.00 in a report released on Wednesday, Benzinga reports. The firm currently has a "buy" rating on the medical research company's stock. The Goldman Sachs Group's price target indicates a potential upside of 11.56% from the company's current price.

Several other research analysts have also weighed in on the company. HSBC assumed coverage on Thermo Fisher Scientific in a research report on Monday, December 18th. They issued a "buy" rating and a $610.00 price objective for the company. Robert W. Baird restated an "outperform" rating and issued a $670.00 price objective on shares of Thermo Fisher Scientific in a report on Thursday, December 14th. Wolfe Research started coverage on shares of Thermo Fisher Scientific in a research report on Wednesday, December 13th. They set an "outperform" rating and a $575.00 price target for the company. Evercore ISI upped their price objective on shares of Thermo Fisher Scientific from $575.00 to $610.00 and gave the stock an "outperform" rating in a report on Thursday, April 4th. Finally, Sanford C. Bernstein reiterated a "market perform" rating on shares of Thermo Fisher Scientific in a report on Monday, January 8th. Five research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company's stock. According to MarketBeat, Thermo Fisher Scientific presently has an average rating of "Moderate Buy" and a consensus price target of $601.56.

Thermo Fisher Scientific Trading Down 2.6 %

NYSE TMO traded down $15.51 on Wednesday, reaching $573.69. 1,282,807 shares of the company were exchanged, compared to its average volume of 1,562,559. Thermo Fisher Scientific has a fifty-two week low of $415.60 and a fifty-two week high of $603.82. The stock has a market capitalization of $218.75 billion, a P/E ratio of 37.35, a price-to-earnings-growth ratio of 2.43 and a beta of 0.80. The business's fifty day moving average price is $570.26 and its 200 day moving average price is $524.68. The company has a current ratio of 1.75, a quick ratio of 1.39 and a debt-to-equity ratio of 0.67.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Wednesday, January 31st. The medical research company reported $5.67 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.64 by $0.03. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The firm had revenue of $10.89 billion during the quarter, compared to analyst estimates of $10.73 billion. During the same quarter in the prior year, the firm posted $5.40 earnings per share. Thermo Fisher Scientific's quarterly revenue was down 4.9% on a year-over-year basis. Analysts forecast that Thermo Fisher Scientific will post 21.52 earnings per share for the current year.

Insider Transactions at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $555.63, for a total value of $5,556,300.00. Following the sale, the chief executive officer now owns 49,155 shares of the company's stock, valued at $27,311,992.65. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other news, CEO Marc N. Casper sold 5,547 shares of the stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $550.62, for a total value of $3,054,289.14. Following the transaction, the chief executive officer now owns 43,608 shares in the company, valued at approximately $24,011,436.96. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $555.63, for a total value of $5,556,300.00. Following the sale, the chief executive officer now owns 49,155 shares of the company's stock, valued at approximately $27,311,992.65. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 50,277 shares of company stock valued at $28,513,384. 0.32% of the stock is currently owned by corporate insiders.

Institutional Trading of Thermo Fisher Scientific

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Phoenix Holdings Ltd. lifted its position in Thermo Fisher Scientific by 21.4% in the third quarter. Phoenix Holdings Ltd. now owns 9,366 shares of the medical research company's stock valued at $4,750,000 after acquiring an additional 1,654 shares during the last quarter. DMC Group LLC boosted its position in shares of Thermo Fisher Scientific by 16.5% in the 3rd quarter. DMC Group LLC now owns 592 shares of the medical research company's stock valued at $300,000 after purchasing an additional 84 shares during the period. Montchanin Asset Management LLC increased its position in Thermo Fisher Scientific by 1.1% during the second quarter. Montchanin Asset Management LLC now owns 4,550 shares of the medical research company's stock worth $2,374,000 after buying an additional 50 shares during the period. Check Capital Management Inc. CA purchased a new stake in Thermo Fisher Scientific in the third quarter valued at approximately $219,000. Finally, Tsfg LLC boosted its holdings in shares of Thermo Fisher Scientific by 8.3% in the fourth quarter. Tsfg LLC now owns 249 shares of the medical research company's stock valued at $132,000 after acquiring an additional 19 shares during the period. Institutional investors and hedge funds own 89.23% of the company's stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.